Loading...
Thumbnail Image
Publication

Ex vivo and in vitro evaluation of the influence of the inhaler device and formulation on lung deposition of budesonide

Aloum, Fatima
Al Ayoub, Yuosef
Mohammad, Mohammad A.
Obeed, Muthana
Paluch, Krzysztof J.
Assi, Khaled H.
Publication Date
15/07/2020
End of Embargo
Supervisor
Rights
© 2020 Elsevier. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
11/06/2020
Institution
Department
Awarded
Embargo end date
Abstract
Two different types of dry powder inhalers (Easyhaler® and RS01®) were used in this work to evaluate the ex vivo and in vitro performance of a budesonide inhaled formulation with recrystallised mannitol, commercial DPI-grade mannitol, or lactose. The aerodynamic performance of the budesonide formulation with recrystallised mannitol was superior when RS01® was used (FPF = 45.8%) compared to Easyhaler® (FPF = 14%). However, the aerodynamic profile was very poor in both devices when commercial mannitol was used. Interestingly, the aerosol performance of the marketed budesonide formulation significantly improved when RS01® was used compared to Easyhaler® (the original device for the formulation). Due to the significant increases in the surface energy of the commercial mannitol formulation, the aerodynamic performance of the formulation was very poor. This work demonstrates the impact of inhaler devices on the performance of inhaled formulations and considers the particle surface energy during formulation development.
Version
Accepted manuscript
Citation
Aloum F, Al Ayoub Y, Mohammad MA et al (2020) Ex vivo and in vitro evaluation of the influence of the inhaler device and formulation on lung deposition of budesonide. Powder Technology. 372: 685-693.
Link to publisher’s version
Link to published version
Type
Article
Qualification name
Notes